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A b s t r a c t
Diabetes Mellitus (DM) is a progressive disease that leads to complex disorders such as 
biochemical changes in the blood. The use of medicinal plants are superior to synthetic drugs 
because of the few side
troxerutin on lipid profile and biochemical enzymes in the blood of type 1 diabetic rats.
32 male Wistar rats (200
control+ troxerutin, diabetes+ troxerutin. Type 1 diabe
streptozotocin (50 mg/kg) in animals in diabetic groups. Lasted for 4 weeks, oral administration 
of troxerutin (150 mg/kg) was carried daily for 4 weeks. At the end of study, anesthesia was 
induced intraperitoneally with
for measuring lipid profile and biochemical enzymes in blood of rats.
Diabete significantly increased LDL, COL, TG and significantly decreased HDL compared to 
the control group. Treatment diab
LDL, COL, TG and significantly increased HDL.
ALT, AST, LDH, and CPK in blood of rats. Treatment diabetic rats with troxerutin for 4 weeks 
significa
group.Troxerutin improve the lipid profile and reduce biochemical enzymes in blood of diabetic 
rats.In this way could be useful in reducing the complications of diabetes.
Key
Introduction 
 
Diabetes mellitus (DM) is a syndrome characterized by 
metabolism, hyperglycemia, resulting from low levels of insulin 
production by beta cells of pancreass [1]. Approximately 95% of 
diabetics are suffering from dyslipidemia and have changes in t
total blood protein [2]. Blood levels of liver enzymes in diabetic 
subjects are changed compared with healthy subjects (non
diabetic) [3]. Prospective studies have found that high levels of 
hepatic enzymes, including alanine amino transferase (ALT), 
aspartate transferase (AST) and alkaline phosphatase (ALP) are 
associated with later development diabetes [4]. It
increased levels of ALT is precursor to type 2 diabetes 
elevation of serum lactate dehydrogenase (LDH) and creatine 
phosphokinase (CPK) concentration has been observed in patie
with diabetes mellitus [5]. 
Hypoglycemic agents are useful in the treatment of DM, but have 
many side effects and use of these drugs restricted by the 
pharmacokinetic properties and secondary failure rate
is a need to look for more efficacious agents with fewer side 
effects[6]. Troxerutin, a trihydroxyethylated derivative of the natural 
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-effects in disease prevention. In this study, we e
-250) were randomly divided into four groups: control, diabetes, 
tes was induced by i.p injection of 
 sodium pentobarbital (mg / kg 60). Blood samples was collected 
etic rats with troxerutin for 4 weeks significantly decreased 
 Furthermore, Diabetes significantly increased 
ntly decreased ALT, AST, LDH, and CPK in blood of rats compared to the control 
words: Diabetes, Troxerutin, biochemical enzymes, lipid profile, rat
disordered 
heir 
-
 is reported that 
[4]. Also, 
nts 
s. So, there 
bioflavonoid rutin, has been reported to possess important 
biological activity, including antioxidative, anti
hiperlipidemia and anti-thrombolytic activity
troxerutin decrease advanced glycation end products and oxidative 
stress in mice. Many studies have shown that troxeruti
variety of biological activities [8-11]
effects of troxerutin in control of diabetes, this study is designed to 
investigate the effects of troxerutin on alterations of 
biochemical enzymes in blood of rats with chronic diabetes.
 
Methods 
 
Animals and study design
 
This research was carried out in accordance with the National 
Research Council’s protocol for the care and use of laboratory 
animals. We obtained 32 Wistar male rats (200 to 250 g) from the 
laboratory animal house of Tabriz University of Medical Sciences. 
The animals were housed in standard conditions (temperature 
22°C, light from 8.00 am to 8.00 pm) and had free access to tap 
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water and food pellets. The animals were divided into into four 
groups (n = 7):  
1-Control (Con): animals that have no intervention and received 
placebo for 4 weeks. 
2-Diabetes (Dia): animals that were diabeticand received placebo 
for 4 weeks. 
3-Troxerutin (Trx): animals that received troxerutin (150 mg/kg/day) 
for 4 weeks. 
4-Diabetes + troxerutin (Dia-Trx): diabetic rats that received 
troxerutin for 4 weeks. 
Troxerutin (150 mg/kg) was gavaged 6 days a week for 4 weeks. 
 
Induction of diabetes 
 
Type 1 diabetes was induced by a single intraperitoneal injection of 
streptozotocin (55 mg/kg) (Sigma, St. Louis, Missouri, USA) to 
animals [12]. Streptozotocin was dissolved in 10mM sodium citrate, 
pH 4.5, with 0.9% NaCl. Diabetes was verified 72 hours later by 
evaluating blood glucose levels using a glucometer (Elegance, 
model CT-X10, Frankenberg, Germany). Rats with blood glucose 
levels≥300 mg/dL (16.67 mmol/L) were considered to have diabetes 
[13]. 
 
Biochemistry Analysis 
At the end of the treatment period of 4 weeks, the animals were 
sacrificed after overnight fasting and blood for serum was collected. 
The blood collected without EDTA was centrifuged at 3500 rpm 
during 15 minutes to obtain the serum that was stored at -20ºC. 
The serum concentration of liver enzymes (alanine 
aminotransferase - ALT, aspartate aminotransferase - AST, and 
alkaline phosphatase - ALP) were determined by colorimetric assay 
using commercially available kits according to the manufacturer’s 
instructions (Labtest Diagnóstica S.A., Lagoa Santa, MG, Brazil). 
Biochemical parameters including total cholesterol (TC), 
triglycerides (TGs), high density lipoprotein-cholesterol (HDLc), and 
low density lipoproteincholesterol (LDLc) that were determined 
enzymatically on a COBAS FARA analyzer Roche Diagnostics, 
Switzerland) [14]. 
 
Statistical analysis 
All values were analyzed by one-way analysis of variance 
(ANOVA), and the Tukey test was used to compare quantitative 
data. Values less than 0.05 were considered statistically significant 
in all cases. Results are expressed as means ±SEM. 
 
Tabel 1: Effect of 4 weeks troxerutine treatment on lipid profile in the serum of   the tested groups 
HDL (mg/dl) LDL (mg/dl) Colostrol (mg/dl) Triglyceride (mg/dl) اھریغتم - اھھورگ  
%30 ± %02 5/5 ± %2 65 ± 2/5 82/2 ±  10/2 Con 
%24  ± 0/ 07** 7/5  ± 0/6 ** 105 ± 2/5 ** 100 ± 1/18** Dia 
%38 ±%05 **+++ 4/2 ± %78 **+++ 6 ±  5/5 +++ 75 ± 9/5 * Con-Trx 
%29 ±%05 +### 6/8 ±%10 *++## 78 ± 3/6 *+++## 91 ± 5/6*++## Dia-Trx 
Data are expressed as mean± SEM for 7 animals. * p<0.05, ** p<0.01, *** p<0.001 vs the Con group. + p<0.05, ++ p<0.01, +++ p<0.001 vs the Dia group. ## 
p<0.01, ### p<0.001 vs the Con-Trx group. 
 
LDL: Low density lipoprotein ،HDL: High density lipoprotein. 
Con: Control, Dia: Diabetes, Con-Trx:Control-Troxerutin, Dia-Trx: 
Diabetes- Troxerutin. 
 
Result 
Effects of troxerutin on lipid profile (TG, COL, LDL, and 
HDL) 
 
Tabel 1 shows that diabetes significantly (p< 0/01) increase TG, 
COL, LDL and significantly (p< 0/01) decrease HDL in blood in 
comparison to the control group. After 4 weeks of treatment of 
diabetic rats with troxerutin, the level of TG (p< 0/01), COL (p< 
0/001), LDL (p < 0/01) and HDL (p < 0/05) significantly reversed in 
blood in comparison to the diabetes group. Also, in the Trx group, 
TG (p < 0/05), LDL (p < 0/01) significantly decreased and HDL (p < 
0/01) 
Significantly increased in blood in comparison to the control group. 
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Figure 1. A) Effect of 4 weeks troxerutine treatment on AST levels in the serum of the control and diabetes groups B) Effect of 4 weeks
troxerutine treatment on ALP levels in the serum of   the control and diabetes groups C) Effects of 4 weeks troxerutine on AL
of   the control and diabetes groups D) Effects of 4 weeks troxerutine on LDH levels in the serum of the control and diabetes
expressed as mean ± SEM for 7 animals. *p<0.05, *** p<0.001 vs the Con group. ++ p<0.01 , +++ p<
 
Effects of troxerutin on blood biochemical enzymes 
(ALT, AST, ALP, CKP, LDH) 
 
One-way ANOVA showed that diabetes significantly(p<0/01) 
increase AST in blood in comparison to the control group. After 4 
weeks of treatment of diabetic rats with troxerutinsignificantly 
(p<0/01) decrease AST in blood in comparison to the diabetes 
group.As shown in figure b, diabetes significantly (p<0/001) 
increase ALP in blood of Dia group in comparison to the control 
group. Treatment of diabetic rats with troxerutin significantly 
(p<0/01) decrease this enzyme. One way ANOVA in figure C 
shows that diabetes significantly (p<0/001) increase ALT in blood in 
comparison to the control group. Also, treatment with troxerutin 
significantly decrease ALT in control group (p<0/05) and diabetic 
rats (p<0/001). As shown in figure d, diabetes significantly (p<0/01) 
increase LDH in blood of diabetes group in comparison to the 
control group. Also, treatment of diabetic rats with troxerutin 
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0.001 vs the Dia group. 
significantly decrease LDH in blood in comparison to the control 
group (p<0/05) and diabetes group (p<0/01).
 
Discussion 
This study is the first to investigate the effect of troxerutin on lipid 
profile and biochemical enzymes in blood of rats with type 1 
diabetes. In this study we shown that 4 weeks treatment of 
diabetes and control groups with troxerutin significantly decrease 
triglyceride, cholesterol, LDL and increase HDL in blood in 
comparison to the control group and diabetes group, respectively. 
Also, our findings showed that treatment of diabetic rats with 
troxerutin significantly decrease blood of biochemical enzymes in 
comparision to control group. 
Diabetes mellitus is associated with a cluster of interrelated plasma 
lipid and lipoprotein abnormalities, including redu
cholesterol, a predominance of small dense LDL particles, and 
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elevated triglycerides[15]. There is an evidence that each of these 
dyslipidemic features is associated with increased risk of 
arteriosclerosis, cardiovascular disease and renal failure leading 
cause of death in patients with diabetes[16-18]. In this study, we 
demenstrated that diabetes leads to dyslipidemia in rats and 
treatment with troxerutin for 4 weeks reverse this abnormality in 
blood of diabetic rats. 
In order to our study , it have been shown that total cholesterol, 
LDL, and triglyceride levels in children and adolescents with type 1 
diabetes to be higher than the control group [19-21]. 
Insulin affects the metabolism of lipoproteins through a variety of 
metabolic pathways [22]. Studies indicate that production of VLDL 
in the gut is controlled by insulin [23]. Several recent studies have 
suggested that insulin resistance may be a factor in causing 
dyslipidemia [22-24]. It has been shown that troxerutin increases 
the level of insulin and its receptor in diabetes type 2 [25].One of 
the reasons for reducing insulin in diabetes is the increase of 
apoptosis in the Langerhans Island cells. In 2011, Lu and 
colleagues showed that troxerutin activates the PI3K / Akt pathway 
[26]. The PI3K / Akt signaling pathway plays an important role in 
the survival, apoptosis, metabolism and proliferation of cells [27]. 
Probably, troxerutrin decreases the rate of apoptosis in  -pancreatic 
cells by activation of PI3K / Akt signaling pathway. 
Also, troxerutin increases the amount of GLUT4 in the membrane 
of skeletal muscle cells and reduces blood glucose level and 
reduces complications from hyperglycemia [25]. In order to our 
work, troxerutrin reduces total blood plasma cholesterol in high-fat 
rats, which is likely to result from inhibitory effect of troxerutrin on 
endogenous cholesterol production by suppressing HMGCoA 
reductase [28]. Chylomicrons and VLDL, as carriers of endogenous 
and exogenous TGs, are substrates of the lipoprotein lipase system 
(LPL) [29]. The level of activity of this enzyme decreases under 
insulin deficiency conditions; which can be the beginning of 
hyperlipidemia in diabetic patients [29]. It has been reported that 
troxerutrin increases the activity of LPL and so decreases plasma 
triglyceride levels [30]. 
It is thought that troxerutrin improve dyslipidemia in stropotozocin -
induced diabetic rats by activating the PI3K / Akt pathway and 
decreasing the amount of apoptosis in  -pancreatic cells, increasing 
the amount of insulin produced, suppressing the HMGCoA 
reductase enzyme, and enhancing LPL activity. 
The study also showed that diabetes significantly increases the 
blood biochemical enzymes and treatment of diabetic rats with 
troxerutin for 4 weeks resulted in a significant decrease in liver 
enzymes. It has been reported that, high levels of liver enzymes 
including ALT, AST and ALKp are seen in rats with diabetes [31]. 
In order to confirm our work, it has also been shown that adding 
troxerutin to coumarin in the treatment of patients with varicose 
veins reduces ALT, LDH, and AST enzymes [32].It is shown that 
functional impairment of liver tissue in diabetic patients increases 
the activity of liver enzymes [33]. Acute hepatocellular necrosis 
have been reported in 80% of diabetic patients [34],therefore, 
increased activity of ALT, AST, ALP, LDH, and CPK in diabetes 
mellitus may be due to the leakage of these enzymes from liver 
cytosol to the bloodstream [35]. It has been reported that troxerutin 
reduces necrosis in the skin of the rats [36]. It is likely that 
troxerutin can reduce the amount of blood biochemical enzymes by 
reducing the liver necrosis of diabetic rats.  
It is reported that, production of free radicals and lipid peroxidation 
of the hepatocytes increase in type 1 diabetes [37]. Increased ROS 
formation in diabetes cause mitochondrial function impairment [38]. 
Hypertrophy of hepatocytes, which is characterized by a significant 
increase in the number of mitochondria and a clear reduction in 
glycogen granules, is one of the characteristics found in type 1 
diabetes mellitus. Following such changes, the permeability of the 
membrane increases and cytoplasmic enzymes of hepatocytes 
leak from the cells into the blood stream [38]. It has been reported 
that troxerutin reduces oxidative stress in the kidneys and brain of 
diabetic rats [39]. Therefore, it seems that troxerutin can reduce the 
amount of blood biochemical enzymes by reducing the oxidative 
stress in the liver of diabetic rats. 
Also, insulin suppresses the genes that produce gluconeogens 
enzymes, as the level of insulin decreases in diabetes, the amount 
of ALT as a gluconeogeneic enzyme, is increased. 
In conclusion, troxerutin, a rutoside derivative, diminish blood 
biochemical enzymes and improve dyslipidemia in STZ-diabetic 
rats. Potential mechanisms underlying the effect of troxerutin in the 
rats with diabetes might be: (i) reducing the oxidative stress in the 
liver (ii) reducing the liver necrosis by activation of PI3K / Akt 
signaling pathway and (iii) increasing insulin production. 
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